X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

RPHM

Closed

Reneo Pharmaceuticals Inc

1.81
-0.01 (-0.55%)
Last Update: 05 Oct 2024 01:32:00
Yesterday: 1.82
Day's Range: 0. - 0.
Send
When Written:
 
6.005
Reneo Pharmaceuticals Inc is a clinical stage biopharmaceutical company that is focused on developing therapies for rare genetic diseases. The company was founded in 2017 and is headquartered in San Diego, California. Reneo's lead product candidate, REN001, is a selective peroxisome proliferator-activated receptor delta agonist that is being developed for the treatment of primary mitochondrial myopathies (PMM). PMM is a rare genetic disease that affects the mitochondria, which are responsible for producing energy in cells. REN001 has received orphan drug designation from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of PMM. Reneo is also exploring the potential of REN001 in other mitochondrial diseases and rare genetic disorders.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X